NCT00319111View on ClinicalTrials.gov

Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

PHASE3CompletedINTERVENTIONAL

Enrollment

151

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

April 30, 2009

Conditions

Pulmonary Hypertension

Interventions

DRUG

bosentan

"Oral bosentan~* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)"